Neumora Therapeutics, Inc.
About Neumora Therapeutics, Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$236.9M
- Total assets
- $191.0M
- Market cap
- $302.0M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $241.2M
- Operating income
- -$241.2M
- Income tax
- $130.0K
- Net income
- -$236.9M
- EPS (basic)
- $-1.45
- EPS (diluted)
- $-1.45
Balance sheet
- Total assets
- $191.0M
- Current assets
- $190.5M
- Total liabilities
- $87.2M
- Current liabilities
- $32.5M
- Shareholders’ equity
- $103.9M
Cash flow
- Operating cash flow
- -$206.4M
- Investing cash flow
- $168.5M
- Financing cash flow
- $77.1M
- Net cash flow
- $39.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $302.0M
- EPS (diluted)
- $-1.45
- Shares outstanding
- 186.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 15, 2023
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $236.9M.
- Trading 55% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Neumora Therapeutics, Inc..
Write a review
News about Neumora Therapeutics, Inc.
News & sentiment via Polygon.io
